121 related articles for article (PubMed ID: 8478310)
1. Dirithromycin disc susceptibility tests: interpretative criteria and quality control parameters.
Barry AL; Pfaller MA; Fuchs PC
J Antimicrob Chemother; 1993 Mar; 31 Suppl C():27-37. PubMed ID: 8478310
[TBL] [Abstract][Full Text] [Related]
2. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.
Barry AL; Thornsberry C; Gavan TL
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics.
Yu KW; Neu HC
Antimicrob Agents Chemother; 1990 Sep; 34(9):1839-42. PubMed ID: 2126695
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results.
Biedenbach DJ; Jones RN; Lewis MT; Croco MA; Barrett MS
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):275-82. PubMed ID: 10212755
[TBL] [Abstract][Full Text] [Related]
5. Multi-centre collaborative study for the in vitro evaluation of new macrolides dirithromycin and erythromycylamine. Australian Group for Antimicrobial Resistance (AGAR).
Fernandes CJ; Benn RA; Nimmo GR
Pathology; 1995 Jan; 27(1):74-8. PubMed ID: 7603759
[TBL] [Abstract][Full Text] [Related]
6. Postantibiotic effect and postantibiotic sub-mic effect of dirithromycin and erythromycin against respiratory tract pathogenic bacteria.
Dornbusch K; Olofsson C; Holm S
APMIS; 1999 May; 107(5):505-13. PubMed ID: 10335955
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.
Counter FT; Ensminger PW; Preston DA; Wu CY; Greene JM; Felty-Duckworth AM; Paschal JW; Kirst HA
Antimicrob Agents Chemother; 1991 Jun; 35(6):1116-26. PubMed ID: 1929252
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of dirithromycin against Chlamydia trachomatis.
Segreti J; Kapell KS
Antimicrob Agents Chemother; 1994 Sep; 38(9):2213-4. PubMed ID: 7811051
[TBL] [Abstract][Full Text] [Related]
9. New drugs--reports of new drugs recently approved by the FDA. Dirithromycin.
Shinkai I; Ohta Y
Bioorg Med Chem; 1996 Apr; 4(4):521-2. PubMed ID: 8735838
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of dirithromycin in comparison with other new and established macrolides.
Bauernfeind A
J Antimicrob Chemother; 1993 Mar; 31 Suppl C():39-49. PubMed ID: 8478311
[TBL] [Abstract][Full Text] [Related]
11. Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Jones RN; Doern GV; Gerlach EH; Hindler J; Erwin ME
Diagn Microbiol Infect Dis; 1994 Apr; 18(4):243-9. PubMed ID: 7924221
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
Logan MN; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1991 Feb; 27(2):161-70. PubMed ID: 1829073
[TBL] [Abstract][Full Text] [Related]
13. Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.
Jones RN; Barry AL
J Clin Microbiol; 1987 Nov; 25(11):2211-3. PubMed ID: 3121667
[TBL] [Abstract][Full Text] [Related]
14. Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin.
Karthein J; Spohr M; Traub WH
Chemotherapy; 1986; 32(4):336-43. PubMed ID: 3731919
[TBL] [Abstract][Full Text] [Related]
15. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
Hoover WW; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1992; 15(3):259-66. PubMed ID: 1533827
[TBL] [Abstract][Full Text] [Related]
16. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria.
Fuchs PC; Jones RN; Barry AL; Gavan TL
J Clin Microbiol; 1989 Jan; 27(1):49-52. PubMed ID: 2492304
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of dirithromycin, a new macrolide antibiotic, against Mycoplasma species.
Rennie KA; Prasad ES; Wenman WM
Diagn Microbiol Infect Dis; 1994 Sep; 20(1):57-9. PubMed ID: 7867300
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial characterization and interrelationships of dirithromycin and epidirithromycin.
Kirst HA; Creemer LC; Paschal JW; Preston DA; Alborn WE; Counter FT; Amos JG; Clemens RL; Sullivan KA; Greene JM
Antimicrob Agents Chemother; 1995 Jul; 39(7):1436-41. PubMed ID: 7492081
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of dirithromycin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Sokolovskaya N; Hammerschlag MR
J Antimicrob Chemother; 1997 May; 39(5):647-9. PubMed ID: 9184366
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
